Перейти до основного вмісту

Recommendations

≥ 18 years

Indications: First episode of uncomplicated CDI

Дозування Ремарки
vancomycin oral 250 mg 4 times daily for 10 days

or

vancomycin oral 125 mg 4 times daily for 10 days

SWAB remarks

First uncomplicated CDI in a non-ambulatory patient

fidaxomicin oral 200 mg twice daily for 10 days

SWAB remarks

Vulnerable patient* (see below) or concurrent use of other antibiotics

metronidazole oral 500 mg three times daily for 10 days

SWAB remarks

Only ambulatory, non-vulnerable patient

≥ 18 years

Indications: Severe, severely complicated, or therapy-refractory CDI

Дозування Ремарки
vancomycin oral 250 mg 4 times daily for 10 days
vancomycin oral min. 250 mg / max. 500 mg 4 times daily

SWAB remarks

If oral treatment is not possible: vancomycin infusion solution via a duodenal tube (250 mg) and/or by enema (500 mg)

metronidazole IV 500 mg three times daily

or

tigecycline IV loading dose 100 mg, 50 mg twice daily

SWAB remarks

When it is uncertain whether orally administered therapy can reach the colon, for example in ileus

SWABID (National) remarks

add metronidazole or tigecycline to oral therapy 

Comments

Stop the responsible antibiotic if possible, and isolate the patient.

Dose: vancomycin capsules oral 4 x 250 mg; a 4 x 125 mg suspension is preferred but is not available in the Netherlands; consider local preparation in consultation with the pharmacy.

* Vulnerable patient groups for whom recurrent CDI can have seriously morbid or otherwise disruptive consequences:
1. Patients undergoing intensive medical treatment (e.g. haemodialysis, (planned) chemotherapy).
2. Immunocompromised persons.
3. Prolonged admission or residence in a nursing home.

For severe, severely complicated, or therapy-refractory CDI: consult the surgeon at an early stage. See the SWAB guideline for further information.

Severe CDI: An infection is designated 'severe CDI' when systemic manifestations occur in addition to diarrhoea. These manifestations may include: fever (core body temperature >38°C), significant leukocytosis (>15 × 109/l), and an increase in serum creatinine (>50% above baseline). Other signs of severe CDI are: colonic dilatation on imaging, pericolonic fat stranding, and colonic wall thickening. 

Severely complicated or fulminant CDI: This disease state is defined by the presence of one of the following signs of illness attributable to CDI: hypotension, septic shock, an elevated serum lactate concentration, ileus, toxic megacolon, bowel perforation or a rapid deterioration of the patient (fulminant course). 

Therapy-refractory CDI: Severe or severely complicated CDI that does not clinically improve after 3-5 days of the recommended anti-CDI antibiotic therapy.

For advice regarding possible faecal transplantation and surgical management see the SWAB guideline Acute diarrhoea.